Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bea
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 2015 Theme and plugin developers from ... pack for Final Cut Pro X entitled Transccordion. ... to any FCPX editors project.” Said Christiana Austin, CEO ... tools needed to easily drag and drop their accordion ... many different controls over the parameters of this transition ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... 28, 2015 The Heart Fit Clinic ... distributor of the machine. The Heart Fit Clinic is ... like a franchise model. The goal is to scale ... heart disease. To buy External Counterpulsation machines ... help individuals through this process and achieve the desired ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law ... by time limits. They stated that in many cases, missing ... even nullify it. Many a time, delays in making an ... under BC law. As a result, experts at Jiwa Law ... consult a personal injury lawyer in order to know more ...
(Date:2/28/2015)... 2015 The Mesothelioma Applied Research ... at the International Symposium on Malignant Mesothelioma on Monday, ... the Hyatt Regency Bethesda in Bethesda, Maryland. The following ... and commitment to the mission to cure mesothelioma. , ... be presented to Miriam Ratner. Miriam runs the Meso ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
... Cow Disease, also known as Bovine Spongiform Encephalopathy (BSE), affects ... control and the animal ultimately dies. Prion proteins are believed ... may contain these prion proteins and the disease might be ... drink its milk, according to a new study. ...
... has indicated the benefits of tomato and broccoli in the ... both the vegetables, are a great blessing in the reduction ... isolation. ,It is estimated that one out ... making it the most notorious of male cancers. Annually, 32,000 ...
... ‘present’ - the common cause of amnesia, also prevents victims ... in the present. ,Researchers, reporting their study ... Sciences at the Wellcome Trust Centre for Neuroimaging, University College ... the brain that is crucial in learning and memory. ...
... federal scanner, which has pointed out a 4% decline in ... Department of Health and Human Service has attributed this drop ... 1996 to 2003- to the spiraling growth in expenditures on ... ,The Agency for Healthcare Research and Quality in Health ...
... melanoma screening of adults age 50 or older appears ... screening programs, according to an article in the January ... only cancer for which incidence and death rates continue ... to be underused, according to background information in the ...
... may come true; for fat people and inventors. ,Scientists ... those of Britain are no exception. //Currently, two thirds of the ... has decided to put a morbidly obese figure of 2.2 million ... Imperial College London. ,Bloom’s quest is to create a chewing ...
Cached Medicine News:Health News:Tomato and Broccoli Combo may Help Fight Prostate Cancer 2Health News:Amnesia Halts Future Thinking: Study 2Health News:One-time Melanoma Screening Appears to Be Cost-effective for Elderly People 2Health News:Chew That Fat Away 2
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
(Date:2/27/2015)... and JERUSALEM , Feb. ... company developing octreotide capsules, its lead product for the ... $70 million Series E financing round. Participants in the ... Ventures, and an undisclosed blue chip public investment fund, ... 7 Med Health Ventures, Abingworth and ARCH Venture Partners. ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... peripheral nerve stimulator automatically ... nerve locator or a ... upon which patient lead ... NSL-5 electrode lead set, ...
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
... Tupper's Universal Hand Holder and Retractor ... the hand in any position needed. ... skin or tendon hooks, fixate the ... With the patient's hand held firmly, ...
Medicine Products: